AMA Creates New Category Code for Augmentative AI Analysis of Cardiopulmonary Disease

The American Medical Association has granted CorVista Health a new Category III Current Procedural Terminology (CPT) code for novel augmentative artificial intelligence (AI) algorithmic analysis of potential coronary artery disease (CAD), pulmonary hypertension (PH), and elevated pulmonary capillary wedge pressure (PCWP).

The new code encompasses the U.S. Food and Drug Administration (FDA)-cleared CorVista System for CAD and PH, as well as the anticipated PCWP Add-On algorithm, which is currently under FDA review and not commercially available in the United States.

CPT codes are used by U.S. physicians, hospitals, and public and private health insurance programs to identify medical services and procedures. Category III CPT codes are temporary codes assigned to emerging technologies, services, and procedures, and are commonly used to support data collection, utilization tracking, and the development of future reimbursement pathways.

The new Category III CPT code, 1104T, takes effect Jan. 1, 2027, and will support reporting for CorVista System use in assessing potential CAD, PH, and elevated PCWP, using augmentative algorithmic analysis of orthogonal voltage gradient and photoplethysmography signals. The code represents an important milestone in CorVista’s reimbursement strategy, according to the company, and supports broader adoption of its point-of-care technology across cardiovascular care settings.

“Receiving a Category III CPT code from the AMA is a significant milestone for CorVista and for the broader movement toward earlier, more accessible cardiovascular diagnosis,” CorVista Health President/CEO Adrian Lam stated. “CorVista was built to help physicians make more informed decisions at the initial point of care, before patients enter a long and fragmented diagnostic journey. This new code strengthens the foundation for broader clinical adoption.”

The CorVista System helps clinicians evaluate symptomatic patients earlier in the diagnostic pathway, using a single, non-invasive signal capture performed at the point of care. The system collects cardiac and hemodynamic signals while the patient is at rest, securely transfers those signals to CorVista’s cloud-based platform, and applies proprietary AI-based algorithms to generate actionable diagnostic insights. The system delivers results without using radiation, contrast agents, injections, fasting, or exercise.

“Cardiovascular disease diagnosis remains too slow and too fragmented,” CorVista Health Chief Customer Officer Nikki Troiano Gainey said. “By enabling a single office-based test to support assessment, CorVista has the potential to bring advanced cardiopulmonary insight to the initial point of care.”

The CorVista System is an FDA-cleared, non-invasive cardiovascular diagnostics platform that analyzes cardiac and hemodynamic signals using AI-based algorithms. The system synchronously collects physiological signals during a brief point-of-care test and applies advanced analytics to identify patterns associated with pulmonary hypertension and coronary artery disease. The system received FDA clearance for coronary artery disease in September 2023 and pulmonary hypertension in April 2024, with additional indications, including heart failure, currently under FDA review. The CorVista System delivers actionable diagnostic insights without using radiation, contrast agents, injections, fasting, or exercise. The CorVista System is developed and manufactured by Analytics For Life Inc. and licensed to CorVista Health Inc.

The CorVista System Add-On for elevated PCWP is currently an investigational device, limited by U.S. law to investigational use, and is not available for commercial distribution.

CorVista Health is aiming to transform cardiovascular care through AI-based diagnostics that shorten the path from symptoms to diagnosis. By enabling earlier detection of complex cardiovascular conditions, CorVista is hoping to empower clinicians with actionable insights and improve patient outcomes across diverse care settings.